Compare · ABT vs CLYM
ABT vs CLYM
Side-by-side comparison of Abbott Laboratories (ABT) and Climb Bio Inc. (CLYM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and CLYM operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $181.14B, about 289.1x CLYM ($626.6M).
- Over the past year, ABT is down 18.4% and CLYM is up 410.1% - CLYM leads by 428.5 points.
- ABT has been more active in the news (13 items in the past 4 weeks vs 2 for CLYM).
- ABT has more recent analyst coverage (25 ratings vs 15 for CLYM).
- Company
- Abbott Laboratories
- Climb Bio Inc.
- Price
- $104.88+0.16%
- $9.82-10.07%
- Market cap
- $181.14B
- $626.6M
- 1M return
- +2.58%
- -30.16%
- 1Y return
- -18.39%
- +410.13%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 13
- 2
- Recent ratings
- 25
- 15
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Abbott introduces Ensure® Max Protein 3-in-1 Muscle Support, bringing the benefits of a supplement stack into one scoop
- Barclays initiated coverage on Abbott Labs with a new price target
- Abbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- SEC Form 4 filed by Director Roman Michael F
- Abbott Labs upgraded by Rothschild & Co Redburn with a new price target
- Abbott hosts conference call for third-quarter earnings
Latest CLYM
- Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug
- Director Ra Capital Management, L.P. exercised 70,000 shares at a strike of $2.79 (SEC Form 4)
- Director Thomas Stephen Basil sold $1,366,820 worth of shares (100,000 units at $13.67) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 467,969 units (SEC Form 4)
- Climb Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy
- Climb Bio to Present at Upcoming Investor Conferences
- SEC Form 8-K filed by Climb Bio Inc.
- SEC Form 10-Q filed by Climb Bio Inc.
- Climb Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates